{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:39:40Z","timestamp":1771677580519,"version":"3.50.1"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.22047","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T22:14:16Z","timestamp":1685225656000},"page":"132-138","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent development of small lymphocytic lymphoma and lung cancer: A report of two cases and a review of the literature"],"prefix":"10.3960","volume":"63","author":[{"given":"Kensuke","family":"Nakao","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94: 1266-1287.","DOI":"10.1002\/ajh.25595"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016; 127: 1752-1760.","DOI":"10.1182\/blood-2015-10-620864"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Mehrotra M, Duose DY, Singh RR <i>et al.<\/i> Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12: e0181968.","DOI":"10.1371\/journal.pone.0181968"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol. 1992; 45: 770-775.","DOI":"10.1136\/jcp.45.9.770"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Stamatopoulos K, Belessi C, Moreno C <i>et al.<\/i> Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007; 109: 259-270.","DOI":"10.1182\/blood-2006-03-012948"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sch\u00f6llkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007; 121: 151-156.","DOI":"10.1002\/ijc.22672"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kumar V, Ailawadhi S, Bojanini L <i>et al.<\/i> Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019; 9: 75.","DOI":"10.1038\/s41408-019-0237-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Solomon BM, Rabe KG, Slager SL <i>et al.<\/i> Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013; 31: 930-937.","DOI":"10.1200\/JCO.2012.43.4449"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018; 103: 931-938.","DOI":"10.3324\/haematol.2017.186684"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Falisi E, Novella E, Visco C <i>et al.<\/i> B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematol Oncol. 2014; 32: 22-30.","DOI":"10.1002\/hon.2086"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Lanemo Myhrinder A, Hellqvist E, Sidorova E <i>et al.<\/i> A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008; 111: 3838-3848.","DOI":"10.1182\/blood-2007-11-125450"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ros\u00e9n A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis. Semin Cancer Biol. 2010; 20: 400-409.","DOI":"10.1016\/j.semcancer.2010.09.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Iguchi Y, Ishihara S, Uchida Y <i>et al.<\/i> Filamin B enhances the invasiveness of cancer cells into 3D collagen matrices. Cell Struct Funct. 2015; 40: 61-67.","DOI":"10.1247\/csf.15001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wartewig T, Kurgyis Z, Keppler S <i>et al.<\/i> PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017; 552: 121-125.","DOI":"10.1038\/nature24649"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Karabon L, Partyka A, Ciszak L <i>et al.<\/i> Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients. J Immunol Res. 2020; 2020: 6545921.","DOI":"10.1155\/2020\/6545921"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Grzywnowicz M, Zaleska J, Mertens D <i>et al.<\/i> Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One. 2012; 7: e35178.","DOI":"10.1371\/journal.pone.0035178"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Xerri L, Chetaille B, Seriari N <i>et al.<\/i> Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia. Hum Pathol. 2008; 39: 1050-1058.","DOI":"10.1016\/j.humpath.2007.11.012"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Grzywnowicz M, Karabon L, Karczmarczyk A <i>et al.<\/i> The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56: 2908-2913.","DOI":"10.3109\/10428194.2015.1017820"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Joshi AD, Hegde GV, Dickinson JD <i>et al.<\/i> ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2007; 13: 5295-5304.","DOI":"10.1158\/1078-0432.CCR-07-0283"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I. CTLA-4 overexpression in CD19+\/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia. 2005; 19: 301-304.","DOI":"10.1038\/sj.leu.2403588"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Mittal AK, Chaturvedi NK, Rohlfsen RA <i>et al.<\/i> Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. PLoS One. 2013; 8: e70352.","DOI":"10.1371\/journal.pone.0070352"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_22047\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:10:58Z","timestamp":1688188258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_22047\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22047","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"22047"}}